Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety of testosterone therapy indicated for hypoactive sexual desire disorder in postmenopausal women

Safety of testosterone therapy indicated for hypoactive sexual desire disorder in postmenopausal... June 2013 No. 280 Founded in 1966 by Professor D M Davies, FRCP, FRCP Ed ISSN 0044–6394 the age of women, the methodology used Safety of testosterone therapy 2,3 and the criteria used to define HSDD. However, HSDD appears to be common indicated for hypoactive sexual desire 2,3 in many countries. Androgens are synthesized in the adrenal disorder in postmenopausal women glands and ovaries in women. Whereas all androgens are produced by the adrenal Vicki Osborne glands, the ovaries only produce dehydroe- Drug Safety Research Unit, Bursledon Hall, Southampton, UK piandrosterone (DHEA), androstenedione Correspondence to Ms Vicki Osborne, MSc, Drug Safety Research Unit, Bursledon Hall, and testosterone. They act throughout the Blundell Lane, Southampton SO31 1AA, UK. body on androgen receptors and are also E-mail: vicki.osborne@dsru.org precursor hormones for synthesis of oestro- gen, which occurs in the ovaries and extra- gonadal tissues. In women, testosterone is the main circulating androgen and can be Summary found circulating free (1–2%) or bound to Hypoactive sexual desire disorder (HSDD) is a common sexual disorder in sex hormone-binding globulin (SHBG; 5,6 postmenopausal women. Testosterone therapy is a possible option for 66%) and albumin. Approximately, 25% of circulating testosterone is directly treatment of HSDD http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Adverse Drug Reaction Bulletin Wolters Kluwer Health

Safety of testosterone therapy indicated for hypoactive sexual desire disorder in postmenopausal women

Adverse Drug Reaction Bulletin , Volume 280 (1) – Jun 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/safety-of-testosterone-therapy-indicated-for-hypoactive-sexual-desire-4jj4Fvz50h

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
0044-6394
eISSN
2159-7774
DOI
10.1097/FAD.0b013e3283628f20
Publisher site
See Article on Publisher Site

Abstract

June 2013 No. 280 Founded in 1966 by Professor D M Davies, FRCP, FRCP Ed ISSN 0044–6394 the age of women, the methodology used Safety of testosterone therapy 2,3 and the criteria used to define HSDD. However, HSDD appears to be common indicated for hypoactive sexual desire 2,3 in many countries. Androgens are synthesized in the adrenal disorder in postmenopausal women glands and ovaries in women. Whereas all androgens are produced by the adrenal Vicki Osborne glands, the ovaries only produce dehydroe- Drug Safety Research Unit, Bursledon Hall, Southampton, UK piandrosterone (DHEA), androstenedione Correspondence to Ms Vicki Osborne, MSc, Drug Safety Research Unit, Bursledon Hall, and testosterone. They act throughout the Blundell Lane, Southampton SO31 1AA, UK. body on androgen receptors and are also E-mail: vicki.osborne@dsru.org precursor hormones for synthesis of oestro- gen, which occurs in the ovaries and extra- gonadal tissues. In women, testosterone is the main circulating androgen and can be Summary found circulating free (1–2%) or bound to Hypoactive sexual desire disorder (HSDD) is a common sexual disorder in sex hormone-binding globulin (SHBG; 5,6 postmenopausal women. Testosterone therapy is a possible option for 66%) and albumin. Approximately, 25% of circulating testosterone is directly treatment of HSDD

Journal

Adverse Drug Reaction BulletinWolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.